Dr. Reddy's Laboratories (RDY) Competitors

$13.56 +0.02 (+0.11%)

As of 12:49 PM Eastern

RDY vs. TEVA, ONC, RVMD, INSM, and BNTX

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? MarketBeat compares Dr. Reddy's Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dr. Reddy's Laboratories include Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Revolution Medicines (RVMD), Insmed (INSM), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, indicating a potential upside of 22.01%. Dr. Reddy's Laboratories has a consensus target price of $16.90, indicating a potential upside of 24.59%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 3 mentions for Dr. Reddy's Laboratories. Teva Pharmaceutical Industries' average media sentiment score of 1.02 beat Dr. Reddy's Laboratories' score of 0.07 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.28	$1.41B	$1.33	25.74
Dr. Reddy's Laboratories	$3.58B	3.16	$484.20M	$0.58	23.39

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Dr. Reddy's Laboratories on 12 of the 16 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Dr. Reddy's Laboratories (NYSE:RDY) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, BeOne Medicines had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for BeOne Medicines and 3 mentions for Dr. Reddy's Laboratories. BeOne Medicines' average media sentiment score of 0.48 beat Dr. Reddy's Laboratories' score of 0.07 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has higher earnings, but lower revenue than BeOne Medicines. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.16	$484.20M	$0.58	23.39
BeOne Medicines	$5.34B	6.36	$286.93M	$4.47	69.28

Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to BeOne Medicines' net margin of 8.94%. Dr. Reddy's Laboratories' return on equity of 12.16% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%
BeOne Medicines	8.94%	12.06%	6.69%

Dr. Reddy's Laboratories currently has a consensus target price of $16.90, indicating a potential upside of 24.59%. BeOne Medicines has a consensus target price of $389.15, indicating a potential upside of 25.66%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Dr. Reddy's Laboratories has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,842.93	-$1.13B	-$7.07	N/A
Dr. Reddy's Laboratories	$3.58B	3.16	$484.20M	$0.58	23.39

In the previous week, Revolution Medicines had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Revolution Medicines and 3 mentions for Dr. Reddy's Laboratories. Revolution Medicines' average media sentiment score of 0.98 beat Dr. Reddy's Laboratories' score of 0.07 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Revolution Medicines' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

Revolution Medicines currently has a consensus price target of $111.35, suggesting a potential downside of 28.09%. Dr. Reddy's Laboratories has a consensus price target of $16.90, suggesting a potential upside of 24.59%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Revolution Medicines has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Summary

Revolution Medicines beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Insmed?

Insmed (NASDAQ:INSM) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Insmed had 14 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 17 mentions for Insmed and 3 mentions for Dr. Reddy's Laboratories. Insmed's average media sentiment score of 1.07 beat Dr. Reddy's Laboratories' score of 0.07 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	13 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$819.56M	28.32	-$1.28B	-$5.75	N/A
Dr. Reddy's Laboratories	$3.58B	3.16	$484.20M	$0.58	23.39

Insmed has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Insmed presently has a consensus target price of $210.95, suggesting a potential upside of 97.00%. Dr. Reddy's Laboratories has a consensus target price of $16.90, suggesting a potential upside of 24.59%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Insmed's net margin of -144.44%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

Summary

Insmed beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioNTech presently has a consensus price target of $128.44, indicating a potential upside of 38.28%. Dr. Reddy's Laboratories has a consensus price target of $16.90, indicating a potential upside of 24.59%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts clearly believe BioNTech is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dr. Reddy's Laboratories has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.24	-$1.29B	-$5.88	N/A
Dr. Reddy's Laboratories	$3.58B	3.16	$484.20M	$0.58	23.39

Dr. Reddy's Laboratories has a net margin of 12.90% compared to BioNTech's net margin of -44.39%. Dr. Reddy's Laboratories' return on equity of 12.16% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

In the previous week, BioNTech had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for BioNTech and 3 mentions for Dr. Reddy's Laboratories. BioNTech's average media sentiment score of 0.59 beat Dr. Reddy's Laboratories' score of 0.07 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDY vs. The Competition

Export

Metric	Dr. Reddy's Laboratories	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$11.32B	$5.90B	$6.38B	$23.15B
Dividend Yield	0.52%	0.71%	2.79%	4.11%
P/E Ratio	23.39	8.56	20.90	30.59
Price / Sales	3.16	21.17	547.42	14.47
Price / Cash	15.80	8.42	44.13	24.79
Price / Book	2.63	4.14	10.09	4.73
Net Income	$484.20M	$102.24M	$3.55B	$1.07B
7 Day Performance	-0.29%	2.38%	4.61%	1.80%
1 Month Performance	5.61%	0.25%	1.36%	0.24%
1 Year Performance	-5.04%	127.01%	36.73%	28.11%

Dr. Reddy's Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDY Dr. Reddy's Laboratories	3.4734 of 5 stars	$13.57 +0.1%	$16.90 +24.6%	-5.7%	$11.32B	$3.58B	23.39	27,811
TEVA Teva Pharmaceutical Industries	4.5914 of 5 stars	$36.26 +1.3%	$41.78 +15.2%	+106.4%	$41.17B	$17.35B	27.26	33,950	Insider Trade
ONC BeOne Medicines	4.0261 of 5 stars	$316.55 +0.5%	$391.00 +23.5%	+30.9%	$34.57B	$5.34B	70.82	12,000
RVMD Revolution Medicines	2.5729 of 5 stars	$149.94 +2.9%	$103.88 -30.7%	+296.8%	$30.98B	$11.58M	N/A	250	Analyst Forecast
INSM Insmed	3.4644 of 5 stars	$117.99 +1.7%	$210.95 +78.8%	+65.9%	$25.14B	$606.42M	N/A	1,664	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. TEVA, ONC, RVMD, INSM, and BNTX

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Summary

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Summary

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Summary

How does Dr. Reddy's Laboratories compare to Insmed?

Summary

How does Dr. Reddy's Laboratories compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. TEVA, ONC, RVMD, INSM, and BNTX

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Do analysts recommend TEVA or RDY?

Does the media prefer TEVA or RDY?

Which has higher valuation & earnings, TEVA or RDY?

Is TEVA or RDY more profitable?

Do insiders and institutionals believe in TEVA or RDY?

Which has more risk and volatility, TEVA or RDY?

Summary

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Does the media refer more to RDY or ONC?

Which has higher earnings & valuation, RDY or ONC?

Which has more volatility & risk, RDY or ONC?

Is RDY or ONC more profitable?

Do analysts recommend RDY or ONC?

Do institutionals and insiders believe in RDY or ONC?

Summary

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Which has higher valuation and earnings, RVMD or RDY?

Does the media refer more to RVMD or RDY?

Do institutionals and insiders have more ownership in RVMD or RDY?

Is RVMD or RDY more profitable?

Do analysts prefer RVMD or RDY?

Which has more volatility & risk, RVMD or RDY?

Summary

How does Dr. Reddy's Laboratories compare to Insmed?

Does the media refer more to INSM or RDY?

Which has stronger earnings and valuation, INSM or RDY?

Which has more risk and volatility, INSM or RDY?

Do institutionals and insiders hold more shares of INSM or RDY?

Do analysts rate INSM or RDY?

Is INSM or RDY more profitable?

Summary

How does Dr. Reddy's Laboratories compare to BioNTech?

Do insiders & institutionals believe in BNTX or RDY?

Do analysts prefer BNTX or RDY?

Which has better valuation and earnings, BNTX or RDY?

Is BNTX or RDY more profitable?

Which has more volatility and risk, BNTX or RDY?

Does the media refer more to BNTX or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools